Boston Scientific Files 8-K on Financial Condition, Operations
Ticker: BSX · Form: 8-K · Filed: Jan 31, 2024 · CIK: 885725
| Field | Detail |
|---|---|
| Company | Boston Scientific CORP (BSX) |
| Form Type | 8-K |
| Filed Date | Jan 31, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: financial-condition, results-of-operations, 8-K, corporate-update
TL;DR
**Boston Scientific just updated its financial status, giving investors a fresh look at its books.**
AI Summary
Boston Scientific Corporation filed an 8-K on January 31, 2024, to report on its financial condition and results of operations. This filing indicates that the company is providing an update on its financial standing, including details about its common stock and senior notes due in 2027. For investors, this matters because it offers a snapshot of the company's financial health, which can influence stock performance and future investment decisions.
Why It Matters
This filing provides a current snapshot of Boston Scientific's financial health, which is crucial for investors to assess the company's performance and make informed decisions about their holdings.
Risk Assessment
Risk Level: low — This 8-K filing is a routine disclosure of financial information and does not indicate any immediate or significant new risks.
Analyst Insight
Investors should review the full financial statements and exhibits once they are available to gain a comprehensive understanding of Boston Scientific's current financial health and operational performance.
Key Numbers
- 2024-01-31 — Date of Report (The date of the earliest event reported in the filing.)
- 1-11083 — Commission File Number (Boston Scientific Corporation's SEC file number.)
- 04-2695240 — I.R.S. Employer Identification No. (Boston Scientific Corporation's IRS Employer Identification Number.)
Key Players & Entities
- BOSTON SCIENTIFIC CORPORATION (company) — the registrant filing the 8-K
- Delaware (company) — state of incorporation for Boston Scientific Corporation
- January 31, 2024 (date) — date of earliest event reported and filing date
- 300 Boston Scientific Way (company) — address of principal executive offices
- Marlborough, Massachusetts (company) — city and state of principal executive offices
- 01752-1234 (company) — zip code of principal executive offices
- 508 683-4000 (company) — registrant's telephone number
Forward-Looking Statements
- Boston Scientific will likely provide more detailed financial results in an upcoming earnings report. (BOSTON SCIENTIFIC CORPORATION) — high confidence, target: Q1 2024 earnings call
FAQ
What is the purpose of this 8-K filing by Boston Scientific Corporation?
This 8-K filing by Boston Scientific Corporation is a current report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically addressing 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits' as of January 31, 2024.
What specific financial instruments are mentioned in the filing as of January 31, 2024?
The filing specifically mentions 'us-gaap:CommonStockMember' and 'bsx:SeniorNotedue2027Member' as of January 31, 2024, indicating updates related to the company's common stock and senior notes due in 2027.
What is Boston Scientific Corporation's state of incorporation and business address?
Boston Scientific Corporation is incorporated in Delaware, and its business address is 300 Boston Scientific Way, Marlborough, Massachusetts, 01752-1234.
What is the Central Index Key (CIK) for Boston Scientific Corporation?
The Central Index Key (CIK) for Boston Scientific Corporation is 0000885725.
Does this 8-K filing indicate that Boston Scientific Corporation is simultaneously satisfying other filing obligations?
The filing includes checkboxes for 'Written communication pursuant to Rule 425 under the Securities Act', 'Soliciting material pursuant to Rule 14a-12 under the Exchange Act', 'Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act', and 'Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act', all of which are unchecked, indicating that this 8-K is not intended to simultaneously satisfy those obligations.
Filing Stats: 518 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-01-31 06:32:20
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 par value per share BSX New York Stock
Filing Documents
- bsx-20240131.htm (8-K) — 29KB
- q42023earningsrelease.htm (EX-99.1) — 458KB
- imagea.jpg (GRAPHIC) — 37KB
- 0000885725-24-000011.txt ( ) — 731KB
- bsx-20240131.xsd (EX-101.SCH) — 3KB
- bsx-20240131_def.xml (EX-101.DEF) — 15KB
- bsx-20240131_lab.xml (EX-101.LAB) — 30KB
- bsx-20240131_pre.xml (EX-101.PRE) — 16KB
- bsx-20240131_htm.xml (XML) — 4KB
02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION
ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On January 31, 2024, Boston Scientific Corporation issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2023. A copy of the release is furnished with this report as Exhibit 99.1. The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
01. FINANCIAL STATEMENTS AND EXHIBITS
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Boston Scientific Corporation dated January 31, 2024 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 31, 2024 BOSTON SCIENTIFIC CORPORATION By: /s/ Susan Thompson Susan Thompson Vice President, Chief Corporate Counsel, and Assistant Secretary